Evidence map›Paper›PMID 38425716›Full record

ReviewFrontiers in genetics2024

Brain function in classic galactosemia, a galactosemia network (GalNet) members review.

Bianca Panis, E Naomi Vos, Ivo Barić, Annet M Bosch, Martijn C G J Brouwers, Alberto Burlina, David Cassiman, David J Coman, María L Couce, Anibh M Das and 25 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. WSeAnalytical and bioanalytical chemistry · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Reshaping the Treatment Landscape of a Galactose Metabolism Disorder.Journal of inherited metabolic disease · 2025
    Review
  8. Health and well-being of maturing adults with classic galactosemia.Journal of inherited metabolic disease · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 17 countries.

Bianca Panis *Department of Pediatrics, MosaKids Children's Hospital, Maastricht University Medical Centre, Maastricht, Netherlands.
E Naomi Vos *Department of Pediatrics, MosaKids Children's Hospital, Maastricht University Medical Centre, Maastricht, Netherlands.
Ivo BarićDepartment of Pediatrics, University Hospital Center Zagreb, Croatia, and School of Medicine, University of Zagreb, Zagreb, Croatia.
Annet M BoschEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Martijn C G J BrouwersEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Alberto BurlinaEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
David CassimanLaboratory of Hepatology, Department of Chronic Diseases, Metabolism and Ageing, Faculty of Medicine, KU Leuven, Leuven, Belgium.
David J ComanQueensland Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia.
María L CouceEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Anibh M DasEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Didem DemirbasDivision of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Manton Center for Orphan Disease Research, Boston, MA, United States.
Aurélie EmpainEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Matthias GautschiDepartment of Paediatrics, Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Swiss Reference Centre for Inborn Errors of Metabolism, Site Bern, Division of Pediatric Endocrinology, Diabetes and Metabolism, University of Bern, Bern, Switzerland.
Olga GrafakouEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Stephanie GrunewaldMetabolic Unit Great Ormond Street Hospital and Institute for Child Health, University College London, London, United Kingdom.
Sandra D K KingmaEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Ina KnerrNational Centre for Inherited Metabolic Disorders, Children's Health Ireland at Temple Street, University College Dublin, Dublin, Ireland.
Elisa Leão-TelesEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Dorothea MöslingerEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Elaine MurphyCharles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery (NHNN), London, United Kingdom.
Katrin ÕunapEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Adriana PanéEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Sabrina PaciEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Rossella PariniEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Isabel A RiveraiMed.ULisboa-Instituto de Investigação do Medicamento, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.
Sabine Scholl-Bürgi29 Department of Child and Adolescent Health, Division of Pediatrics I-Inherited Metabolic Disorders, Medical University Innsbruck, Innsbruck, Austria.
Ida V D SchwartzMedical Genetics Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.
Triantafyllia SdogouEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Loai A ShakerdiAdult Metabolics/Genetics, National Centre for Inherited Metabolic Disorders, The Mater Misericordiae University Hospital, Dublin, Ireland.
Anastasia SkoumaEuropean Reference Network for Hereditary Metabolic Disorders (MetabERN) Member, Padova, Italy.
Karolina M StepienSalford Royal Organisation, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Eileen P TreacySchool of Medicine, Trinity College Dublin, National Rare Diseases Office, Mater Misericordiae University Hospital, Dublin, Ireland.
Susan WaisbrenDivision of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Manton Center for Orphan Disease Research, Boston, MA, United States.
Gerard T Berry *Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Manton Center for Orphan Disease Research, Boston, MA, United States.
M Estela Rubio-Gozalbo *Department of Pediatrics, MosaKids Children's Hospital, Maastricht University Medical Centre, Maastricht, Netherlands.
Boston Children's Hospital · USMaastricht University Medical Centre · NLInstitute of Child Health · GRUniversity College London · GBArchbishop Makarios III Hospital · CYCentro de Investigación Biomédica en Red · ESChildren's Health Ireland at Crumlin · IEEmma Kinderziekenhuis · NLHospital de Clínicas de Porto Alegre · BRHospital de São João · PTInnsbruck Medical University · ATInstituto de Investigación Sanitaria de Santiago · ESIstituti di Ricovero e Cura a Carattere Scientifico · ITKU Leuven · BEMaastricht University · NLMater Misericordiae University Hospital · IEMedical University of Vienna · ATMedizinische Hochschule Hannover · DEQueen Fabiola Children's University Hospital · BEQueensland Children’s Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classic galactosemia (CG, OMIM #230400, ORPHA: 79,239) is a hereditary disorder of galactose metabolism that, despite treatment with galactose restriction, affects brain function in 85% of the patients. Problems with cognitive function, neuropsychological/social emotional difficulties, neurological symptoms, and abnormalities in neuroimaging and electrophysiological assessments are frequently reported in this group of patients, with an enormous individual variability. In this review, we describe the role of impaired galactose metabolism on brain dysfunction based on state of the art knowledge. Several proposed disease mechanisms are discussed, as well as the time of damage and potential treatment options. Furthermore, we combine data from longitudinal, cross-sectional and retrospective studies with the observations of specialist teams treating this disease to depict the brain disease course over time. Based on current data and insights, the majority of patients do not exhibit cognitive decline. A subset of patients, often with early onset cerebral and cerebellar volume loss, can nevertheless experience neurological worsening. While a large number of patients with CG suffer from anxiety and depression, the increased complaints about memory loss, anxiety and depression at an older age are likely multifactorial in origin.

Indexed as

brainclassic galactosemiacognitive problemsgalactosemovement disordersneurodevelopmentneuropsychiatry

Identifiers

PMID38425716
PMCPMC10902464
OpenAlexW4391842117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.